WaveMan
WaveMan · Company
ADMA · Adma Biologics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ADMA Adma Biologics (ADMA) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001368514
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
146
13F, latest reported quarter

What the filings say about ADMA

Insiders, 180 days
+$250.9K net bought
1 buyer

Adma Biologics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ADMA BIOLOGICS, INC. insiders bought a net $250.9K of stock across 76 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-29.

Insider
Filed
Shares
Value
Since filing
Grossman Jerrold B
Director
BUY
2026-05-28 SECtraded 2026-05-27
6,400
$50.6K
+41.4%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (4 buys, 2 sales), the last on May 12, 2026.
  • +14.5% median (+13.6% mean) 90-day return after 4 previous buys.
  • The trade is 1.2% of the 520,284 shares held after it.
  • No other insider bought within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Grossman Jerrold B bought about $50.6K of ADMA on May 27, 2026; 146 funds added in the latest 13F quarter.
Grossman Jerrold B
Director
BUY
2026-05-14 SECtraded 2026-05-12
12,500
$100.1K
+36.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (3 buys, 2 sales), the last on May 11, 2026.
  • +13.0% median (+12.8% mean) 90-day return after 3 previous buys.
  • The trade is 2.4% of the 513,884 shares held after it.
  • No other insider bought within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Grossman Jerrold B bought about $100.1K of ADMA on May 12, 2026; 146 funds added in the latest 13F quarter.
Grossman Jerrold B
Director
BUY
2026-05-12 SECtraded 2026-05-11
12,500
$100.1K
+32.7%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (2 buys, 2 sales), the last on Jun 9, 2025.
  • +7.3% median (+7.3% mean) 90-day return after 2 previous buys.
  • The trade is 2.5% of the 501,384 shares held after it.
  • No other insider bought within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Grossman Jerrold B bought about $100.1K of ADMA on May 11, 2026; 146 funds added in the latest 13F quarter.
Grossman Adam S
President and CEO
SELL
2026-03-17 SECtraded 2026-03-16
6,000
$91.0K
-24.1%
Context
  • 33 earlier Form 4 trades (code P or S) here by this insider (4 buys, 29 sales), the last on Feb 17, 2026.
  • +2.7% median (+2.7% mean) 90-day return after 2 previous buys.
  • The trade is 0.3% of the 2,112,777 shares held after it.
  • 1 other insider sold within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Grossman Adam S sold about $91.0K of ADMA on Mar 16, 2026; 1 other insider sold within 30 days and 146 funds added in the latest 13F quarter.
Grossman Adam S
President and CEO
SELL
2026-03-17 SECtraded 2026-03-16
15,000
$227.4K
-24.1%
Context
  • 33 earlier Form 4 trades (code P or S) here by this insider (4 buys, 29 sales), the last on Feb 17, 2026.
  • +2.7% median (+2.7% mean) 90-day return after 2 previous buys.
  • The trade is 0.7% of the 2,118,777 shares held after it.
  • 1 other insider sold within 30 days.
  • 146 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Grossman Adam S sold about $227.4K of ADMA on Mar 16, 2026; 1 other insider sold within 30 days and 146 funds added in the latest 13F quarter.
76 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 71 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$250.9K over 180 days
more than 82% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
146 funds bought in last quarter
more than 81% of Pharma & Biotech
Revenue
+19.6% year over year
more than 66% of Pharma & Biotech
Margin
28.8% net margin
more than 90% of Pharma & Biotech
Buybacks
$155.2M repurchased, FY to 2026-06-30
more than 72% of Pharma & Biotech
Short interest
8.9% of the float short (float per yahoo 2026-10-27) · 6.5 days to cover · settled 2026-10-15
more than 67% of Pharma & Biotech
What changed in the last 30 days
Oct 29Insider buying stopped: no purchases in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch ADMA

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-25.7%12M
-50%-22%+6%+34%2025-102025-122026-022026-042026-062026-082026-10 2025-12-15 · Grossman Adam S sold $296.9K2026-02-17 · Grossman Adam S sold $241.2K2025-10-24 · Grossman Adam S sold $240.0K2025-11-19 · Grossman Adam S sold $240.0K2026-03-16 · Grossman Adam S sold $227.4K2026-03-09 · Kestenberg-Messina Kaitlin M. sold $157.8K2025-12-15 · Grossman Adam S sold $118.7K2026-03-05 · ELMS STEVE bought $109.7K2026-03-06 · ELMS STEVE bought $107.7K2026-05-11 · Grossman Jerrold B bought $100.1K2026-05-12 · Grossman Jerrold B bought $100.1K2026-02-17 · Grossman Adam S sold $96.5K2025-10-24 · Grossman Adam S sold $96.0K2025-11-19 · Grossman Adam S sold $96.0K2026-03-16 · Grossman Adam S sold $91.0K2026-05-27 · Grossman Jerrold B bought $50.6K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ADMA: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
38,355,684 sh
$321.0M
STATE STREET CORP
17,116,022 sh
$143.3M
VANGUARD CAPITAL MANAGEMENT LLC
10,103,809 sh
$84.6M
VANGUARD PORTFOLIO MANAGEMENT LLC
10,088,490 sh
$84.4M
Rubric Capital Management LP
9,339,414 sh
$78.2M

Congress trades in ADMA

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ADMA planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ADMA mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
First Trust NYSE Arca Biotechnology Index Fund
$65.5M position · as of 2026-06-30
2.3%
Virtus Biotech Etf
$1.4M position · as of 2026-07-31
1.4%
Motley Fool Small-Cap Growth ETF
$770.5K position · as of 2026-05-31
1.3%
Ranger Small Cap Fund
$152.6K position · as of 2026-07-31
1.2%
Transamerica Small Cap Growth
$994.9K position · as of 2026-07-31
1.2%
Ranger Micro Cap Fund
$140.7K position · as of 2026-07-31
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 4
0 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $250.9K bought by insiders over 180 days, 146 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ADMA financials

Revenue growth
+19.6%
XBRL, annual
Net margin
28.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$512.3M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
+33.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$116.5M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.48x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
0.70x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
+41.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
+27.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
+36.0%
operating income after a 22.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on capital employed
+41.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
16.11x
close 2026-10-28 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
$2.6B
market value at close 2026-10-28 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
+4.6%
TTM free cash flow over market value at close 2026-10-28
PEG, trailing
n/a
trailing EPS growth -19%, PEG needs growth
Price as of 2026-10-28. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$510.2M$426.5M$258.2M$154.1M
Gross profit$292.8M$219.6M$88.9M$35.3M
Operating income$191.4M$139.0M$21.6M-$39.4M
Net income$146.9M$197.7M-$28.2M-$65.9M
EPS (diluted)0.600.81-0.13-0.33
Operating cash flow$50.4M$118.7M$8.8M-$59.5M
Cash$87.6M$103.1M$51.4M$86.5M
Long-term debt$69.3M$72.3Mn/an/a
Buybacks$31.9M$0$0n/a
SEC XBRL, fiscal years, as known on 2026-10-29

ADMA Stock Sonar score 6/7 axes

Find similar shapesCompare

ADMA ranks highest on profitability (91st percentile) and insider conviction (69th), and lowest on institutional and government (41st), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
91
Inputs
  • Return on equity+41.9% · 93 pct, sector of 545
  • Return on assets+27.2% · 94 pct, sector of 691
  • Return on invested capital+36.0% · 80 pct, sector of 45
  • Return on capital employed+41.1% · 98 pct, sector of 576
Financial health
61
Inputs
  • Debt to equity0.48x · 33 pct, sector of 352
  • Cash flow to debt0.70x · 90 pct, sector of 371
Growth
66
Inputs
  • Revenue growth, YoY+19.6% · 66 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
69
Inputs
  • Net Form 4 buying (codes P and S), 180d$251K · 81 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
41
Inputs
  • Funds adding, latest quarter146 · 81 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$20K · 2 pct, sector of 133
Risk and compliance
43
Inputs
  • Short interest, % of float+8.9% · 42 pct, sector of 816
  • Recalls per $1B revenue, 3ynot measured for this sector, almost no peer has an event
  • EPA cases per $1B revenue, 5ynot measured for this sector, almost no peer has an event
  • New text in Risk Factors, latest 10-K+11.6% · 45 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ADMA filings, in plain words

Are Adma Biologics insiders buying or selling ADMA?

In the 180 days to 2026-10-29, Adma Biologics insiders were net buyers, a net $250.9K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-29, Adma Biologics insiders were net buyers of ADMA, a net $250.9K across purchases and sales reported on Form 4 by 1 buyer. Each figure is counted from SEC and House filings as of 2026-10-29, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies